Dissecting the dendritic cell controversy in chronic hepatitis B virus infection

Cellular and Molecular Immunology

Volumn 12, Issue 3, 2015, Pages 283-291

  Gehring, Adam J ^a,b   D'Angelo, June Ann ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

Author keywords

Dendritic Cell; Hepatitis B virus; Vaccination

Indexed keywords

ALPHA INTERFERON; DENDRITIC CELL VACCINE; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; LYMPHOCYTE PROLIFERATION; MONOCYTE DERIVED DENDRITIC CELL; MYELOID DENDRITIC CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; REVIEW; VIRUS LOAD; ANIMAL; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; VIROLOGY;

HEPATITIS B VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; DENDRITIC CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; VIRAL LOAD;

EID: 84928897411     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.95     Document Type: Review

References (59)

1. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL et al. Longitudinal analysis of CD81 T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004; 78: 5707-5719.
2. Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol. 2003; 170: 477-486.
3. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y et al. Upregulation of the Tim-3/Galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS ONE 2012; 7: e47648.
4. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
5. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011; 53: 1494-1503.
6. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J et al. Bimmediated deletion of antigen-specific CD81 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835-1845.
7. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54: 1286-1296.
8. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009; 3: 561-569.
9. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings. J Hepatol 2013; 59: 450-456.
10. King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS ONE 2014; 9: e101904.
11. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X et al. Combination of DNA prime-Adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the Woodchuck Model. PLoS Pathog 2013; 9: e1003391.
12. Zhang Z, Chen D, Yao J, Zhang H, Jin L, Shi M et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol 2007; 122: 173-180.
13. Koumbi LJ, Papadopoulos NG, Anastassiadou V, Machaira M, Kafetzis DA, Papaevangelou V. Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers. Clin Vaccine Immunol 2010; 17: 1079-1085.
14. Beckebaum S, Cicinnati VR, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104: 138-150.
15. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HGM, Kusters JG et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738-746.
16. Tavakoli S, Mederacke I, Herzog-Hauff S, Glebe D, Grun S, Strand D et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 2007; 151: 61-70.
17. Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A et al. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 2013; 123: 3766-3776.
18. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006; 44: 907-914.
19. Chen L, Zhang Z, Chen W, Zhang Z, Li Y, Shi M et al. B7-H1 upregulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol 2007; 178: 6634-6641.
20. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508-1517.e1-10.
21. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HLA. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 2011; 6: e15324.
22. Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, Leroy V et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 2012; 143: 1586-1588.
23. Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z. HBsAg inhibits IFN-A production in plasmacytoid dendritic cells through TNF-A and IL-10 induction in monocytes. PLoS ONE 2012; 7: e44900.
24. Guo J, Gao Y, Guo Z, Zhang LR, Wang B, Wang SP. Frequencies of dendritic cells and Toll-like receptor 3 in neonates born to HBsAgpositive mothers with different HBV serological profiles. Epidemiol Infect 2014; 1-9.
25. Duan XZ, Wang M, Li HW, Zhuang H, Xu D, Wang FS. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 2004; 24: 637-646.
26. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS ONE 2011; 6: e26315.
27. Boltjes A, Groothuismink ZM, van Oord GW, Janssen HL, Woltman AM, Boonstra A. Monocytes from chronicHBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. PLoS ONE 2014; 9: e97006.
28. Duan XZ, He HX, Zhuang H. Restoration in vitro of impaired T-cell responses in patients with chronic hepatitis B by autologous dendritic cells loaded with hepatitis B virus proteins (R2). J Gastroenterol Hepatol 2006; 21: 970-976.
29. Tavakoli S. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol 2004; 85: 2829-2836.
30. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY et al. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepatitis 2004; 11: 217-224.
31. Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 2003; 109: 487-495.
32. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126: 280-289.
33. Chai N, Chang HE, Nicolas E, Han Z, Jarnik M, Taylor J. Properties of subviral particles of hepatitis B virus. J Virol 2008; 82: 7812-7817.
34. Vanlandschoot P, van Houtte F, Roobrouck A, Farhoudi A, Stelter F, Peterson DL et al. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. J Gen Virol 2002; (83): 2279-2289.
35. Vanlandschoot P, van Houtte F, Hoek F, Nieuwland R, Leroux-Roels G. Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity. J Med Virol 2003; 70: 513-519.
36. Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009; 393: 84-90.
37. Chen W, Shi M, Shi F, Mao Y, Tang Z, Zhang B et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res 2009; 39: 355-365.
38. Shi M, Qian S, ChenWW, Zhang H, Zhang B, Tang ZR et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-Associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol 2006; 147: 277-286.
39. Carotenuto P, Artsen A, Niesters HG, Osterhaus AD, Pontesilli O. In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens. J Med Virol 2009; 81: 332-339.
40. Chen M, Li YG, Zhang DZ, Wang ZY, Zeng WQ, Shi XF et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005; 11: 1806-1808.
41. Luo J, Li J, Chen RL, Nie L, Huang J, Liu ZW et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 2010; 28: 2497-4504.
42. van Montfoort N, van der Aa E, Woltman AM. Understanding MHC Class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol 2014; 5: 182.
43. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001; 194: 769-779.
44. Moffat JM, Cheong WS, Villadangos JA, Mintern JD, Netter HJ. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine 2013; 31: 2310-2316.
45. Bohm W, Schirmbeck R, Elbe A, Melber K, Diminky D, Kraal G et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol 1995; 155: 3313-3321.
46. Stober D, Trobonjaca Z, Reimann J, Schirmbeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur J Immunol 2002; 32: 1099-1108.
47. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520-4529.
48. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 Activation rescues antiviral CD81 T cells from PD-1-mediated exhaustion. PLoS Pathog 2013; 9: e1003490.
49. Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD81 T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013; 14: 574-583.
50. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, TanKC et al. IL-7 Licenses activation of human liver intrasinusoidal mucosal-Associated invariant T cells. J Immunol 2013; 190: 3142-3152.
51. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 2014; 10: e1004210.
52. Velazquez VM, Hon H, Ibegbu C, Knechtle SJ, Kirk AD, Grakoui A. Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology 2012; 56: 2071-2081.
53. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
54. Crispe IN. Liver antigen-presenting cells. J Hepatol 2011; 54: 357-365.
55. Xia S, Guo Z, Xu X, Yi H, Wang Q, Cao X. Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance. Blood 2008; 112: 3175-3185.
56. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 2004; 172: 1009-1017.
57. Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008; 29: 464-475.
58. Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am J Pathol 2004; 164: 511-519.
59. Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP et al. Human Liver dendritic cells promote T cell hyporesponsiveness. J Immunol. 2009; 182: 1901-1911.